Obinutuzumab

Generic Name
Obinutuzumab
Brand Names
Gazyva, Gazyvaro
Drug Type
Biotech
Chemical Formula
-
CAS Number
949142-50-1
Unique Ingredient Identifier
O43472U9X8
Background

Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Le...

Indication

Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.

Associated Conditions
Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
Associated Therapies
-

Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL

First Posted Date
2016-05-02
Last Posted Date
2023-01-17
Lead Sponsor
University of Ulm
Target Recruit Count
41
Registration Number
NCT02758665
Locations
🇩🇪

BAG Onkologische Gemeinschaftspraxis, Dresden, Germany

🇩🇪

Universitätsklinikum Essen, Essen, Germany

🇩🇪

Universitätsklinikum Freiburg, Freiburg, Germany

and more 8 locations

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

First Posted Date
2016-04-25
Last Posted Date
2021-04-13
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
30
Registration Number
NCT02750670
Locations
🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

First Posted Date
2016-04-06
Last Posted Date
2020-12-23
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
36
Registration Number
NCT02729896
Locations
🇵🇱

Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych, Warsaw, Poland

🇺🇸

UCLA, Los Angeles, California, United States

🇺🇸

University Miami, Miami, Florida, United States

and more 16 locations

Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2016-02-01
Last Posted Date
2017-03-20
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Target Recruit Count
1
Registration Number
NCT02670317
Locations
🇮🇹

IRCCS Napoli Pascale, Napoli, Italy

🇮🇹

Ospedale San Gerardo, Monza, Italy

🇮🇹

Ospedale Maggiore della Carità, Novara, Italy

and more 26 locations

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

First Posted Date
2015-12-16
Last Posted Date
2022-04-13
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
38
Registration Number
NCT02631577
Locations
🇺🇸

University Miami, Miami, Florida, United States

🇫🇷

Hopital du Bocage, Dijon, France

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 13 locations

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia

First Posted Date
2015-12-14
Last Posted Date
2024-11-19
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
81
Registration Number
NCT02629809
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

First Posted Date
2015-12-09
Last Posted Date
2020-05-18
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
25
Registration Number
NCT02624986
Locations
🇺🇸

Mayo Clinic Arizona, Phoenix, Arizona, United States

🇩🇪

Charité Research Organisation GmbH Campus-Virchow-Klinikum, Berlin, Germany

🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

and more 21 locations

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

First Posted Date
2015-11-23
Last Posted Date
2024-12-13
Lead Sponsor
TG Therapeutics, Inc.
Target Recruit Count
603
Registration Number
NCT02612311
Locations
🇬🇧

TG Therapeutics Investigational Trial Site, Wolverhampton, United Kingdom

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

First Posted Date
2015-11-20
Last Posted Date
2023-10-10
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
133
Registration Number
NCT02611323
Locations
🇮🇹

Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Emilia-Romagna, Italy

🇮🇹

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy

🇮🇹

SCDU Ematologia, Novara, Piemonte, Italy

and more 20 locations
© Copyright 2024. All Rights Reserved by MedPath